Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.92
-0.07 (-0.78%)
Mar 3, 2026, 4:00 PM EST - Market closed
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$825,444
Profits / Employee
$58,444
Market Cap
461.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 900 | -700 | -43.75% |
| Dec 31, 2023 | 1,600 | -900 | -36.00% |
| Dec 31, 2022 | 2,500 | 84 | 3.48% |
| Dec 31, 2021 | 2,416 | 216 | 9.82% |
| Dec 31, 2020 | 2,200 | 366 | 19.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 960 |
| Organogenesis Holdings | 854 |
| Kamada | 420 |
| Lifecore Biomedical | 406 |
| Evolus | 329 |
| Ironwood Pharmaceuticals | 253 |
| Akebia Therapeutics | 181 |
| Aquestive Therapeutics | 142 |
EBS News
- 21 hours ago - Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - GlobeNewsWire
- 3 days ago - Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture - Seeking Alpha
- 5 days ago - Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 5 days ago - Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 days ago - Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness - GlobeNewsWire
- 5 days ago - Emergent BioSolutions Announces New $50 Million Stock Repurchase Program - GlobeNewsWire
- 19 days ago - Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks - GlobeNewsWire
- 19 days ago - Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire